1. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of S-tofisopam, a prodrug or pharmaceutically acceptable salt thereof, substantially free of its R-enantiomer, with a pharmaceutically acceptable carrier.

2. (Currently amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 85% or more by weight of the total weight of tofisopam.

3. (Currently amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 90% or more by weight of the total weight of tofisopam.

4. (Currently amended) The pharmaceutical composition of claim 1 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 95% or more by weight of the total weight of tofisopam.

5. (Currently amended) The pharmaceutical composition of claim 1 wherein the amound of S-tofisopam or a prodrug or

a pharmaceutically acceptable salt thereof is 99% or more by weight of the total weight of tofisopam.

6. (Canceled) The composition according to claim 1, wherein the conformation of the S-tofisopam is 80% (-) and 20% (+).

7. (Canceled) The composition according to claim 1 further comprising another anti-convulsant.

8. (Canceled) The composition according to claim 7, wherein the other anti-convulsant is a benzodiazepine.

9. (Canceled) The composition according to claim 7, wherein the other anti-convulsant is a 1,4-benzodiazepine.

10. (Canceled) The composition according to claim 7, wherein the other anti-convulsant is selected from the group consisting of diazepam, lorazepam, clonazepam, clorazepate and nitrazepam.

11. (Canceled) The composition according to claim 1, wherein said composition is a controlled-release pharmaceutical composition.

12. (Canceled) A method of treating convulsions or seizures comprising administering to a subject in need of treatment therefore, a therapeutically effective amount of the composition of claim 1.

13. (Canceled) A method of preventing convulsions or seizures in a subject at risk for developing convulsions or seizures comprising administering to a subject in need of treatment therefore, a therapeutically effective amount of the composition of claim 1.

14. (Canceled) The method according to claim 12 or 13 wherein the subject is a human.

15. (Canceled) The method according to claim 12 or 13 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 90% or more by weight of the total weight of tofisopam.

16. (Canceled) The method according to claim 12 or 13 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 95% or more by weight of the total weight of tofisopam.

17. (Canceled) The method according to claim 12 or 13 wherein the amount of S-tofisopam or a prodrug or a pharmaceutically acceptable salt thereof is 99% or more by weight of the total weight of tofisopam.

18. (Canceled) The method according to claim 12 or 13, wherein the composition according to claim 1 is administered together or sequentially with another anticonvulsant.

19. (Canceled) The method according to claim 18, wherein the other anti-convulsant is a benzodiazepine.

20. (Canceled) The method according to claim 18, wherein the other anti-convulsant is a 1,4-benzodiazepine.

21. (Canceled) The method according to claim 18, wherein the other anti-convulsant is selected from the group consisting of diazepam, lorazepam, clonazepam, clorazepate and nitrazepam.

22. (Canceled) The method according to claim 12 or 13, wherein the composition is administered intraperitonealy, subcutaneously, intranasally, intramuscularly,

intrathecaly, sublingualy, rectally, by intravenous infusion, transdermal delivery or orally as a tablet, a capsule or a liquid suspension.

23. (Canceled) The method according to claim 12 or 13, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof administered is from approximately 10 mg to 1200 mg.

24. (Canceled) The method according to claim 23 wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof administered is from approximately 50 mg to 600 mg.

25. (Canceled) The method according to claim 23 wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof administered is from approximately 100 mg to 400 mg.

26. (Canceled) The method according to claim 12 or 13 wherein said amount is administered in 1 to 4 doses per day.

27. (Canceled) The method according to claim 26 wherein said amount is administered in 1 to 2 doses per day.

28. (Currently amended) The pharmaceutical composition according to claim 1, wherein the composition is for intraperitoneal, subcutaneous, intranasal, intramuscular, intrathecal, sublingual, rectal, intravenous infusion, transdermal delivery or oral administration.

29. (Currently amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 10 mg to 1200 mg.

30. (Currently amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 50 mg to 600 mg.

31. (Currently amended) The pharmaceutical composition according to claim 1, wherein the amount of S-tofisopam, prodrug, or a pharmaceutically acceptable salt thereof is from 100 mg to 400 mg.